- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Flerie AB: The merger between Flerie and Lipum has been completed | 82 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 12.03. | Lipum AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum | 119 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| FLERIE Aktie jetzt für 0€ handeln | |||||
| 11.02. | Flerie AB: Flerie's portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis | 183 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Microbiotica's... ► Artikel lesen | |
| 02.02. | Flerie AB: Flerie's portfolio company Nanologica acquires Syntagon | 426 | GlobeNewswire (Europe) | Flerie AB (publ)'s portfolio company Nanologica has acquired Ardena Södertälje AB ('Syntagon'), a contract manufacturer with 45 employees. The acquisition strengthens Nanologica's production capacity... ► Artikel lesen | |
| 21.01. | Flerie AB: Flerie AB (publ) Year-end report 2025 | 128 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,377 million (4,198) and net asset value per share was SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8... ► Artikel lesen | |
| 20.01. | Flerie AB: Flerie's portfolio company Chromafora acquires Montrose Environmental Group Denmark | 223 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Chromafora has acquired Montrose Environmental Group Denmark, a Danish specialist in PFAS and provider of technical solutions for contaminated water treatment. The... ► Artikel lesen | |
| 09.01. | Flerie AB: Flerie's portfolio company KAHR Bio presents strong survival data from Phase II trial with DSP107 and secures USD 22 million in equity funding | 179 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company KAHR Bio announced a median overall survival of 17.5 months in its Phase II trial with DSP107, combined with the anti-PD-L1 immunotherapy atezolizumab, in patients... ► Artikel lesen | |
| 29.12.25 | Flerie AB: Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 29 December 2025 at 10:00 CET | 168 | GlobeNewswire (Europe) | The Extraordinary General Meeting of Flerie AB (publ) reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 29 December 2025 at 10:00 CET at which the following resolutions were made.
Resolution... ► Artikel lesen | |
| 11.12.25 | Flerie AB: Flerie receives FDI-approval for the merger with Lipum | 201 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 05.12.25 | Flerie AB: Flerie intends to divest its holdings in the Limited Partnership segment | 162 | GlobeNewswire (Europe) | Flerie AB (publ) intends to divest its entire holdings in the investment funds that constitute the company's Limited Partnership segment. The divestment will be subject to a decision at an extraordinary... ► Artikel lesen | |
| 18.11.25 | Flerie AB: Flerie and Lipum have agreed on a merger plan | 197 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 22.10.25 | Flerie-Aktie nach Q3-Zahlen im Aufwind trotz Wertberichtigungen | 2 | Investing.com Deutsch | ||
| 22.10.25 | Flerie AB: Flerie AB (publ) Interim Report January - September 2025 | 156 | GlobeNewswire (Europe) | The period in brief• Net asset value was SEK 3,918 million (4,262) and net asset value per share was SEK 50.58 (54.59 at 30 September 2024). Change in net asset value per share in the quarter was -4.2... ► Artikel lesen | |
| 23.09.25 | Flerie AB: Flerie's portfolio company Xintela has presented positive 24-month data for its stem cell product XSTEM | 214 | GlobeNewswire (Europe) | Stockholm, Sweden, September 23, 2025. Flerie AB's (publ) portfolio company Xintela has announced that its stem cell product XSTEM continues to demonstrate safety, reduction in knee pain, improved joint... ► Artikel lesen | |
| 19.08.25 | Flerie AB: The merger between Flerie and Toleranzia has been completed | 239 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 08.08.25 | Toleranzia AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Toleranzia | 276 | GlobeNewswire (Europe) | The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) ("Flerie") to carry out the merger plan concerning the merger between Flerie and Toleranzia AB... ► Artikel lesen | |
| 31.07.25 | Flerie AB: The Board of Directors of Flerie has resolved to redeem all Series C shares within the framework of Flerie's share redemption scheme | 211 | GlobeNewswire (Europe) | At an Extraordinary General Meeting of Flerie AB (publ) ("Flerie" or the "Company") held on 10 June 2024, a resolution was passed to introduce a redemption scheme for the Company's shares. Redemption... ► Artikel lesen | |
| 31.07.25 | Flerie AB: Flerie AB (publ) Interim Report January - June 2025 | 221 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was 4.4 per... ► Artikel lesen | |
| 16.07.25 | Flerie AB: Flerie AB's subsidiary Flerie Invest AB announces final outcome of the mandatory cash offer to the shareholders of Nanologica AB (publ) | 699 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
| 25.06.25 | Toleranzia AB: Toleranzia applies for delisting of the Company's shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie | 219 | GlobeNewswire (Europe) | Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HAEMATO | 12,000 | +2,56 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| EYEPOINT | 11,290 | 0,00 % | EyePoint sues Ocular over claims related to lead asset | ||
| PHOTOCURE | 5,770 | -1,87 % | Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway | OSLO, Norway, March 16, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology... ► Artikel lesen | |
| BAYER | 38,385 | -0,21 % | Aktien Frankfurt Ausblick: Stabilisierung - Unicredit bietet für Commerzbank | FRANKFURT (dpa-AFX) - Der Dax dürfte recht stabil in den elften Handelstag seit Kriegsausbruch im Iran starten. Der X-Dax signalisierte für den deutschen Leitindex rund eine Stunde vor Handelsbeginn... ► Artikel lesen | |
| MERCK KGAA | 104,05 | -3,07 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 150 Euro auf "Overweight" belassen. Nach den Quartalszahlen des Pharma- und Spezialchemiekonzerns... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,800 | -2,17 % | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| NOVO NORDISK | 31,560 | 0,00 % | HV-Termine: Hauptversammlungen bei All for One, BB Biotech, MeVis, Novo Nordisk, Sartorius | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| PFIZER | 23,315 | +0,15 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| SANOFI | 76,88 | +0,05 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| GSK | 22,470 | -0,71 % | BARCLAYS stuft GSK auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Underweight" belassen. Jüngste Absatzdaten belegten auf Wochensicht... ► Artikel lesen | |
| SCHOTT PHARMA | 12,960 | -1,97 % | SCHOTT PHARMA AG & CO KGAA im strukturellen Gleichgewicht | ||
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| DERMAPHARM | 40,900 | -0,73 % | Ihre wichtigsten Termine: Nvidia, Qualcomm, Audi, Dermapharm, Docusign und Fraport stehen heute im Fokus! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland: Fraport... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 22,250 | +7,13 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| NOVARTIS | 126,24 | +0,27 % | Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Novartis in focus |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLERIE AB finden Sie auf Wallstreet Online.